BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang Y, Gauthier A, Keeping S, Carroll S. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res 2014;14:913-27. [PMID: 25189087 DOI: 10.1586/14737167.2014.950232] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Nymark LS, Sharma T, Miller A, Enemark U, Griffiths UK. Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used. Vaccine 2017;35:6828-41. [PMID: 29146380 DOI: 10.1016/j.vaccine.2017.10.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
2 Musher DM. Should Committees That Write Guidelines and Recommendations Publish Dissenting Opinions? Mayo Clinic Proceedings 2016;91:634-9. [DOI: 10.1016/j.mayocp.2016.01.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Largeron N, Lévy P, Wasem J, Bresse X. Role of vaccination in the sustainability of healthcare systems. J Mark Access Health Policy 2015;3. [PMID: 27123188 DOI: 10.3402/jmahp.v3.27043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
4 Birck AM, Nordin Christensen L, Pedersen MH, Olsen J, Johnson KD, Bencina G, Clausen TH, Larsen CS. Health economic evaluation of introducing a PPSV23-based vaccination programme to adults aged 65 and above, and an extension to the 60-64 age group in Denmark. Expert Rev Vaccines 2021;20:1327-37. [PMID: 34488534 DOI: 10.1080/14760584.2021.1977627] [Reference Citation Analysis]
5 Jiang Y, Yang X, Taniguchi K, Petigara T, Abe M. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan. J Med Econ 2018;21:687-97. [PMID: 29723081 DOI: 10.1080/13696998.2018.1465272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Choi MJ, Kang SO, Oh JJ, Park SB, Kim MJ, Cheong HJ. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea. Hum Vaccin Immunother 2018;14:1914-22. [PMID: 29953307 DOI: 10.1080/21645515.2018.1456602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
7 Marbaix S, Peetermans WE, Verhaegen J, Annemans L, Sato R, Mignon A, Atwood M, Weycker D. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. PLoS One 2018;13:e0199427. [PMID: 29979689 DOI: 10.1371/journal.pone.0199427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cunningham AL, McIntyre P, Subbarao K, Booy R, Levin MJ. Vaccines for older adults. BMJ 2021;372:n188. [PMID: 33619170 DOI: 10.1136/bmj.n188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Heo JY, Seo YB, Choi WS, Lee J, Noh JY, Jeong HW, Kim WJ, Kim MJ, Lee HY, Song JY. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS One 2017;12:e0177342. [PMID: 28498857 DOI: 10.1371/journal.pone.0177342] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
10 Musher DM, Rodriguez-Barradas MB. Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Hum Vaccin Immunother 2016;12:331-5. [PMID: 26606172 DOI: 10.1080/21645515.2015.1098794] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
11 . The Economic Value of Vaccination: Why Prevention is Wealth. J Mark Access Health Policy 2015;3. [PMID: 27123186 DOI: 10.3402/jmahp.v3.29414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
12 Mangen MJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, van Deursen AM, van der Ende A, Grobbee DE, Sanders EA, Sato R, Verheij TJ, Vissink CE, Bonten MJ, de Wit GA. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J 2015;46:1407-16. [PMID: 26160871 DOI: 10.1183/13993003.00325-2015] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 8.9] [Reference Citation Analysis]
13 Cafiero-Fonseca ET, Stawasz A, Johnson ST, Sato R, Bloom DE. The full benefits of adult pneumococcal vaccination: A systematic review. PLoS One 2017;12:e0186903. [PMID: 29088258 DOI: 10.1371/journal.pone.0186903] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
14 Chen C, Beutels P, Wood J, Menzies R, MacIntyre CR, McIntyre P, Newall AT. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine 2018;36:6307-13. [PMID: 30213457 DOI: 10.1016/j.vaccine.2018.08.084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Bianchi FP, Stefanizzi P, Spinelli G, Mascipinto S, Tafuri S. Immunization coverage among asplenic patients and strategies to increase vaccination compliance: a systematic review and meta-analysis. Expert Rev Vaccines 2021;20:297-308. [PMID: 33538617 DOI: 10.1080/14760584.2021.1886085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Chalmers JD, Campling J, Dicker A, Woodhead M, Madhava H. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med 2016;16:77. [PMID: 27169895 DOI: 10.1186/s12890-016-0242-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
17 Sun X, Tang Y, Ma X, Guo X, Huang Z, Ren J, Qiu J, Jiang H, Lu Y. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China. Front Public Health 2021;9:647725. [PMID: 34109145 DOI: 10.3389/fpubh.2021.647725] [Reference Citation Analysis]
18 de Soárez PC, Sartori AM, Freitas AC, Nishikawa ÁM, Novaes HM. Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil. PLoS One 2015;10:e0130217. [PMID: 26114297 DOI: 10.1371/journal.pone.0130217] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
19 Nishikawa AM, Sartori AMC, Mainardi GM, Freitas AC, Itria A, Novaes HMD, de Soárez PC. Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older. Vaccine 2018;36:2510-22. [DOI: 10.1016/j.vaccine.2018.03.070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
20 Namkoong H, Ishii M, Funatsu Y, Kimizuka Y, Yagi K, Asami T, Asakura T, Suzuki S, Kamo T, Fujiwara H, Tasaka S, Betsuyaku T, Hasegawa N. Theory and strategy for Pneumococcal vaccines in the elderly. Hum Vaccin Immunother 2016;12:336-43. [PMID: 26406267 DOI: 10.1080/21645515.2015.1075678] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
21 Garattini L, Padula A, Da Costa MR. Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering? Pharmacoeconomics 2016;34:221-4. [PMID: 26518294 DOI: 10.1007/s40273-015-0341-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
22 José RJ, Brown JS. Adult pneumococcal vaccination: advances, impact, and unmet needs. Curr Opin Pulm Med 2017;23:225-30. [PMID: 28198725 DOI: 10.1097/MCP.0000000000000369] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]